Difference between revisions of "User:Samuelrubinstein"
Jump to navigation
Jump to search
(Updated bio) Tag: visualeditor |
m (Section Editor) |
||
| Line 1: | Line 1: | ||
[[File:Samuelrubinstein.jpg|thumb|Samuel Rubinstein, MD]] | [[File:Samuelrubinstein.jpg|thumb|Samuel Rubinstein, MD]] | ||
| − | Samuel Rubinstein MD is a Clinical Assistant Professor of Medicine in the Division of Hematology at the University of North Carolina-Chapel Hill Lineberger Comprehensive Cancer Center. His current research focuses on exploring outcomes and conducting clinical trials for patients with plasma cell dyscrasias including multiple myeloma and AL amyloidosis. He is also the site PI at UNC for the COVID-19 and Cancer Consortium (CCC-19). He is the HemOnc.org | + | Samuel Rubinstein MD is a Clinical Assistant Professor of Medicine in the Division of Hematology at the University of North Carolina-Chapel Hill Lineberger Comprehensive Cancer Center. His current research focuses on exploring outcomes and conducting clinical trials for patients with plasma cell dyscrasias including multiple myeloma and AL amyloidosis. He is also the site PI at UNC for the COVID-19 and Cancer Consortium (CCC-19). He is the HemOnc.org Section Editor of [[:Category:Plasma_cell_dyscrasia_regimens|Plasma Cell Dyscrasias]]. |
Latest revision as of 20:14, 25 April 2024
Samuel Rubinstein MD is a Clinical Assistant Professor of Medicine in the Division of Hematology at the University of North Carolina-Chapel Hill Lineberger Comprehensive Cancer Center. His current research focuses on exploring outcomes and conducting clinical trials for patients with plasma cell dyscrasias including multiple myeloma and AL amyloidosis. He is also the site PI at UNC for the COVID-19 and Cancer Consortium (CCC-19). He is the HemOnc.org Section Editor of Plasma Cell Dyscrasias.